Carbendazim

Drug Profile

Carbendazim

Alternative Names: ATI-0312; Benzimate; FB 642

Latest Information Update: 03 Oct 2008

Price : $50

At a glance

  • Originator Procter & Gamble
  • Developer Arisyn Therapeutics
  • Class Antifungals; Antineoplastics; Benzimidazoles; Carbamates; Small molecules
  • Mechanism of Action Tubulin inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Cancer; HIV infections

Most Recent Events

  • 23 Sep 2008 Phase-I clinical trials in HIV infections in USA (PO)
  • 23 Sep 2008 Arisyn Therapeutics acquires small-molecule inhibitors against infectious diseases and/or cancer from UAF Technologies and Research LLC, including carbendazim (ATI 0312)
  • 01 May 2006 Phase-I clinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top